Additionally, our data suggests that palbociclib sensitized tumors to SOC treatment, shown by partial and sustained tumor regressions with salvage therapy, durable regression with upfront therapy, and decreased pRb-Ser780 (Figure 4 and Figure 6). This evidence concerns the gene RB1 and neoplasm.